Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Aug 08 2025

0mins

Source: Yahoo Finance

Agreement Renewal: Cosmo Pharmaceuticals has renewed its multi-year manufacturing and supply agreement with Takeda for the production of Mesalazine MMX 1200 mg, reinforcing their collaboration and commitment to high-quality pharmaceutical solutions.
Company Overview: Cosmo is a life sciences company specializing in MedTech AI and gastrointestinal diseases, with a focus on innovation and sustainability, operating advanced manufacturing facilities approved by global regulatory authorities.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

About the author

Top News

Ford Announces $19.5B EV Restructuring Charges

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

Related Articles

MANTL Partners with Method Financial to Enhance Loan Experience

Rockwell Automation Recognized in 20 Gartner Hype Cycles for 2025

People Also Watch